Tamtam Try Tamtam free
Doctolib logo

Doctolib account plan

Healthcare technology solutions

At a glance

Doctolib is a European health software company serving 520,000 health professionals and 90 million patients, with €422 million of recurring revenue in 2025.

Doctolib, founded in 2013 in France, started with online appointment booking and now sells practice software, patient records, teleconsultation, messaging, billing and AI assistants to health professionals, while patients use it for free. It claims 520,000 health professionals and 90 million patients across five European countries: France, Germany, Italy, the Netherlands and the United Kingdom. Recurring revenue (ARR) was €348 million in 2024 and €422 million in 2025, the company became profitable in autumn 2025, and it has about 3,000 employees. It is privately held, valued at an implied €3.6 billion after a spring 2026 secondary sale; Nvidia took a minority stake in October 2026. Co-founder Stanislas Niox-Chateau is CEO.

Strategic priorities

AI across the product
"AI is central to our roadmap. We want to embed AI in every part of the product." Doctolib is building assistants for clinicians (Consultation Assistant, Virtual Phone Assistant) and a health companion for patients, funded in part by the Nvidia investment.
From booking to full practice software
Evolve from an appointment tool to a full-service ecosystem: a clinical and financial management system for documentation and billing, smart check-in, Siilo messaging and interoperability with national EHRs.
European expansion
Expand into new European markets beyond France and Germany; the UK became the fifth market in 2026 through the Medicus acquisition.
Headcount growth
Niox-Chateau plans to double the workforce from 2,800 people in four to five years, and the Nvidia money is to accelerate hiring.
Data privacy and European hosting
Health data stays hosted in Europe, models are adapted from open models, and the company says it does not and will not sell patient data.

Latest results

Recurring revenue (ARR) rose to €422 million in 2025 from €348 million in 2024, when it grew 22.5% and EBITDA was a loss of €53.8 million. In October 2025 the CEO announced that Doctolib had become profitable. In spring 2026 about €300 million of existing shares changed hands at an implied €3.6 billion valuation, below the €5.8 billion of 2022; this did not fund the company. No guidance is published.

Investments and deals

Medicus Health acquisition (UK)
Acquired London GP practice management software Medicus Health in May 2026, terms undisclosed, with a commitment to invest "more than £100 million sterling" in the UK, hire 150 people and open a primary-care R&D centre.
Nvidia minority stake
Nvidia took a minority stake on 13 October 2026, with no board seat, to accelerate hiring and the development of Doctolib's models and AI assistants.
Patient health companion
Launched a patient assistant in October 2025, first for parents of children under 4.

Challenges and risks

Larger software competitors
Competes with Cegedim and CompuGroup Medical in France and the Optum-TPP near-duopoly in UK GP software; the CEO calls Doctolib three times smaller than its European competitors.
Competition authority fine
Fined €4.665 million by the Autorité de la concurrence in November 2025 for exclusivity practices, tied sales and the MonDocteur acquisition; the appeal is pending.
Lower valuation
The spring 2026 secondary sale implied €3.6 billion, about 38% below the €5.8 billion valuation of March 2022.
Country-by-country complexity
Financing regimes, reimbursement rules and patient journeys differ across France, Germany and Italy, so team and brand must be rebuilt in each country.
Sovereignty and AI trust
Computing power from a US partner raises a sovereignty question, and the new AI tools must still prove their usefulness in documentation, administration and clinical decision support.

What leadership says

“We have 2,800 people today. We will double that population [in] four [to] five years.”

Stanislas Niox-Chateau, Co-founder and CEO · HEC Paris interview, September 2025

“If you want to change the world, you need to build systemic technology, not just a layer on top.”

Stanislas Niox-Chateau, Co-founder and CEO · HEC Talks, 15 September 2025

“Doctolib has been profitable for a few weeks”

Stanislas Niox-Chateau, Co-founder and CEO · BFM TV interview reported by Maddyness, October 2025 (translated)

“AI is central to our roadmap. We want to embed AI in every part of the product.”

Dr. Katharina Schweidtmann, Head of Strategy & Partnerships · ICT&health interview, May 2025

Where a supplier can help

Recruiting and onboarding at scale
Tied to the headcount growth priority and the 150 UK hires: recruiting, onboarding and HR tooling for a workforce set to double.
AI infrastructure in Europe
Tied to the AI priority and the European hosting commitment: compute, model evaluation and privacy tooling that keep health data in Europe.
Localisation for new markets
Tied to European expansion and country-by-country complexity: reimbursement, billing and EHR interoperability expertise for the UK and future markets.
Compliance and competition-law support
Tied to the competition authority fine: commercial compliance and contract governance for sales practices.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Doctolib?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Doctolib

What does Doctolib do?

Doctolib sells subscription software to health professionals: online booking, practice management, patient records, teleconsultation, messaging, billing and AI assistants. Patients use it for free.

What is Doctolib's revenue?

Recurring revenue (ARR) was €422 million in 2025, up from €348 million in 2024; the company became profitable in autumn 2025.

How many employees does Doctolib have?

About 3,000 employees, and the CEO plans to double the workforce within four to five years.

Who leads Doctolib?

Co-founder Stanislas Niox-Chateau is CEO; Jessy Bernal and Ivan Schneider are the other co-founders.

In which countries does Doctolib operate?

France, Germany, Italy, the Netherlands and, since the 2026 Medicus acquisition, the United Kingdom.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)